Literature DB >> 9379676

Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia.

X M Sheng1, M Kawamura, H Ohnishi, K Ida, R Hanada, S Kojima, M Kobayashi, F Bessho, M Yanagisawa, Y Hayashi.   

Abstract

Using the polymerase chain reaction-single strand conformation polymorphism method and direct sequencing, 12 acute myeloid leukemia (AML) cell lines and 108 fresh childhood myeloid tumor specimens, including 67 AML, 29 myelodysplastic syndrome (MDS), and 12 juvenile chronic myelocytic leukemia (JCML) were examined for mutation in H-, K-, and N-RAS genes. The mutation was found in eight of the 120 samples (6.7%), which consisted of four cell lines (33.3%) and four fresh myeloid tumors (3.7%). The frequency of the mutation in the cell lines was apparently higher than that in fresh myeloid tumors. K-RAS gene mutations were found in two of the 67 fresh AML specimens (3%). Interestingly, these two patients had 11q23 translocations. The N-RAS gene mutation was found in one of the 29 specimens (3.4%) of MDS and in one of the 12 specimens (8.3%) of JCML. All mutations were found in codon 12, 13 or 61 of the N-RAS and K-RAS genes. Frequency of mutation of RAS genes in fresh myeloid malignancies was very low. These findings suggest that mutation of RAS genes does not play an important role in the development of childhood myeloid malignancies.

Entities:  

Mesh:

Year:  1997        PMID: 9379676     DOI: 10.1016/s0145-2126(97)00036-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Hirozumi Sano; Akira Shimada; Tomohiko Taki; Chisato Murata; Myoung-Ja Park; Manabu Sotomatsu; Ken Tabuchi; Akio Tawa; Ryoji Kobayashi; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

Review 2.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

3.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

4.  Advances in haematological pharmacotherapy in 21st century.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-28       Impact factor: 0.900

5.  Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.

Authors:  Tamer A Ahmed; John Hayslip; Markos Leggas
Journal:  Leuk Res       Date:  2014-09-16       Impact factor: 3.156

6.  Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Authors:  Rebecca J Chan; Melissa B Leedy; Veerendra Munugalavadla; Cara S Voorhorst; Yanjun Li; Menggang Yu; Reuben Kapur
Journal:  Blood       Date:  2005-01-11       Impact factor: 22.113

7.  Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.

Authors:  Y Lucy Liu; Yan Yan; Cody Webster; Lijian Shao; Shelly Y Lensing; Hongyu Ni; Wei Feng; Natalia Colorado; Rupak Pathak; Zhifu Xiang; Martin Hauer-Jensen; Shaoguang Li; Daohong Zhou; Peter D Emanuel
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

8.  Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.

Authors:  Zhenyun Yang; Takako Kondo; Cara S Voorhorst; Sarah C Nabinger; Leila Ndong; Fuqin Yin; Edward M Chan; Menggang Yu; Oliver Würstlin; Christian P Kratz; Charlotte M Niemeyer; Christian Flotho; Eri Hashino; Rebecca J Chan
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

9.  Bladder cancer cell‑secreted exosomal miR‑21 activates the PI3K/AKT pathway in macrophages to promote cancer progression.

Authors:  Fan Lin; Hu-Bin Yin; Xin-Yuan Li; Gong-Min Zhu; Wei-Yang He; Xin Gou
Journal:  Int J Oncol       Date:  2019-12-03       Impact factor: 5.650

10.  Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.

Authors:  Sachit A Patel; Don W Coulter; Alfred C Grovas; Bruce G Gordon; James L Harper; Phyllis I Warkentin; James L Wisecarver; Warren G Sanger; Peter F Coccia
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.